Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 54

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 54
---
     |                              2024 |     |
|                                     |     |                 Unaudited |     |   |     |                         Unaudited |     |
| Operating expenses                  |     |                           |     |   |     |                                   |     |
| Research and development expenses   |     |                           | 331 |   |     |                                   | 327 |
| General and administrative expenses |     |                           | 464 |   |     |                                   |  34 |
| Operating loss                      |     |                           | 795 |   |     |                                   | 361 |
| Financial expense (income), net     |     |                           | (25 | ) |     |                                   |  10 |
| Net loss and comprehensive loss     |     |                           | 770 |   |     |                                   | 371 |

Research and Development Expenses

Successor’s and Predecessor’s research and development expenses totaled $331 thousand for the period commencing July 24, 2024 through September 30, 2024, representing an increase of $4 thousand, or 1.2%, compared to Predecessor’s $327 thousand for the same period. The research and development expenses comprise mainly from salaries and related expenses, from share based payment expenses and other expenses. The increase was immaterial.

General and Administrative Expenses

Successor’s and Predecessor’s general and administrative expenses totaled $464 thousand for the period commencing July 24, 2024 through September 30, 2024, representing an increase of $430 thousand, or 1,264.7%, compared to Predecessor’s $34 thousand for the same period. The increase was primarily attributable to Successor’s share-based payment compensation, Successor’s salaries and related expenses and Successor’s professional services for such period compared to no such expenses in the Predecessor for the same period.

Operating Loss

As a result of the foregoing, Successor’s and Predecessor’s operating loss totaled $795 thousand for the period commencing July 23, 2024 through September 30, 2024, representing an increase of $434 thousand, or 120.2%, compared to Predecessor’s $361 thousand for the same period.

<div align='center'>33</div>

Financing expense (income), Net

Successor’s and Predecessor’s recognized financing income, net of $25 thousand for the period commencing July 24, 2024 through September 30, 2024, representing